The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design

BACKGROUND: A phase 2 trial has suggested that treatment with the melanocortin-4 receptor (MC4R) agonist setmelanotide is associated with a decrease in hunger and weight-related outcomes in participants with Bardet-Biedl syndrome (BBS) and Alström syndrome. Here, we present the study design of an on...

Descripción completa

Detalles Bibliográficos
Autores principales: Haws, Robert M., Gordon, Gregory, Han, Joan C., Yanovski, Jack A., Yuan, Guojun, Stewart, Murray W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114053/
https://www.ncbi.nlm.nih.gov/pubmed/34013094
http://dx.doi.org/10.1016/j.conctc.2021.100780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114053/
https://www.ncbi.nlm.nih.gov/pubmed/34013094
http://dx.doi.org/10.1016/j.conctc.2021.100780

Ejemplares similares